Revenues: 8,739M (-2%); Pharmaceuticals: 4,366M (-4%); Vaccines: 2,012M (+15%); Consumer Healthcare: 2,360M (-8%).
Key product sales: Shingrix: 645M (+21%); Ellipta: 725M (+8%); Tivicay: 365M (-14%); Triumeq: 580M (-9%); Nucala: 292M (+34%); Benlysta: 205M (+21%); Seretide/Advair: 351M (-15%); Ventolin: 211M (-7%); Augmentin: $115M (-27%); Bexsero: 159M (+42%); Fluarix, FluLaval: 252M (+83%); Infanrix, Pediarix: 172M (+10%).
Net Income: 677M (-48%); EPS: 0.136 (-19.4%); non-GAAP Net Income: 1,163M (-5%); non-GAAP EPS: 0.233 (-6%).
CF Ops: 8,441M (+5%).
2021 Guidance: Pharmaceutical revenue growth: flat to low-single digits; Consumer Healthcare revenue growth: low to mid-single digits; Vaccines revenue growth: flat to low-single digits; Adjusted EPS is expected to decline by mid to high-single digit percentage in CER.